Article Text

Download PDFPDF
Original research
Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales
  1. Andrew Yeoman,
  2. Daniel Raun Maggs,
  3. Syed A A Gardezi,
  4. Hasan Nadim Haboubi,
  5. Muhammad Imran Yahya,
  6. Fidan Yousuf,
  7. Marek Alexander Czajkowski
  1. Gwent Liver Unit, Aneurin Bevan University Health Board, Newport, UK
  1. Correspondence to Dr Andrew Yeoman, Gwent Liver Unit, Aneurin Bevan University Health Board, Newport, Wales NP20 2UB, UK; andrew.yeoman{at}


Introduction SARS-CoV-2 (COVID-19) is a novel coronavirus that emerged in Wuhan, China in late 2019 and since become a global pandemic. As such, its clinical behaviour is a subject of much interest. Initial reports suggested a significant proportion of patients have abnormal liver blood tests. Gwent has experienced one of the highest incidences of COVID-19 infection in the UK, which itself has among the highest COVID-19 impacts worldwide.

Method We set out to report the incidence, clinical pattern and severity of liver blood test abnormalities in hospitalised patients with confirmed COVID-19 in our institution over a 3-week period. Data on clinical outcomes such as admission to intensive therapy unit (ITU), hospital discharge and mortality were recorded.

Results 318 hospitalised COVID-19 positive had liver blood tests available for analysis. Ninety-seven patients (31%) had one or more abnormal liver blood tests and were abnormal admission in 64%. Liver tests were predominantly cholestatic (72%) in contrast to other studies to date. Male gender and abnormal liver blood tests were associated with ITU admission.

Conclusions Almost one-third of admissions with COVID-19 have abnormal LBTs which are typically mild and are associated with male gender. Importantly, we have identified that cholestatic patterns dominate but were not clearly associated with ITU admission or death.

  • hepatitis
  • cholestasis

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @GwentLiverUnit, @SyedGerdezi

  • Contributors AY developed the idea for the project, collected data and wrote the manuscript. DRM collected data and wrote, reviewed and helped edit the manuscript. SAAG collected data and assisted with writing the manuscript. HNH assisted with statistical analysis and helped write and edit the manuscript. MIY collected data and helped edit the manuscript. FY collected data, assisted in writing and editing the manuscript. MAC collected data and assisted in writing and editing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Approval to undertake this review was obtained from the Health Boards Research and Development Department.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information. All data were held on Health Board computers on secure drives and each file was password protected. Data were anonymised.

Linked Articles